• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Gary Liska Discusses Alere's Role in the STABLE study

Article

Gary Liska, with Alere Home Monitoring Inc, says Alere's commitment to patients' safety is why they supported the STABLE study.

Gary Liska, with Alere Home Monitoring Inc, says Alere’s commitment to patient safety is why they supported the STABLE study. They saw an opportunity with Medicare’s expansion of its coverage policy for self-testing, and decided to provide self-testing services to Medicare and practitioners.

Mr Liska also explains why the STABLE study results are so important.

“Within the last 3 years, there have been 5 clinical papers written on cost-effectiveness. The market remains very volatile right now, and clinicians, and particularly healthcare, is looking for the most cost-effective agent,” Mr Liska says. “The 5 studies that have been published are all consistent with a certain threshold of warfarin quality of between 65% and 73%, so those are thresholds that Alere looks at very carefully. It was really the impetus behind conducting this study.”

Related Videos
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster - stock.adobe.com
Amit Singal, MD, UT Southwestern Medical Center
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.